scholarly article | Q13442814 |
P953 | full work available at URL | http://cancerres.aacrjournals.org/cgi/content/abstract/43/8/3493 |
P698 | PubMed publication ID | 6190553 |
P2093 | author name string | R. L. Momparler | |
P. A. Jones | |||
V. L. Wilson | |||
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | chemotherapy | Q974135 |
P304 | page(s) | 3493-3496 | |
P577 | publication date | 1983-08-01 | |
P1433 | published in | Cancer Research | Q326097 |
P1476 | title | Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action | |
P478 | volume | 43 |
Q24628329 | A Perspective on the Comparative Antileukemic Activity of 5-Aza-2'-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza) |
Q54485278 | Cell cycle effects and cellular pharmacology of 5-AZA-2?-deoxycytidine |
Q37479882 | Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells |
Q36466835 | Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia |
Q35831786 | DNA Methylation Modulates Nociceptive Sensitization after Incision |
Q30498513 | DNA methylation and differentiation |
Q36920588 | Differential nuclear protein binding to 5-azacytosine-containing DNA as a potential mechanism for 5-aza-2'-deoxycytidine resistance |
Q43860783 | Effect of cytidine analogs on cell growth and differentiation on a human neuroblastoma line |
Q52674783 | Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer. |
Q37824255 | Epigenomics in cancer management |
Q34768789 | Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies |
Q38529787 | Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer |
Q38825067 | Mechanistic insights into epigenetic modulation of ethanol consumption |
Q43247519 | Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. |
Q35164242 | Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. |
Q33393266 | Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. |
Q39102674 | Preclinical antitumor activity of 5-aza-2'-deoxycytidine against human and neck cancer xenografts [corrected]. |
Q54527773 | Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression. |
Q67535907 | Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin |
Q37634505 | Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents |
Q33431584 | The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. |
Q41894605 | The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. |
Q37765469 | Therapy with azanucleosides for myelodysplastic syndromes |
Q35939534 | Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation |
Search more.